Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of orally given paracetamol on the vascular function and on 24-hour blood pressure in patients with coronary artery disease

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Zurich
• Treatments: Acetaminophen

Criteria

Inclusion Criteria:

• Age: 30 - 80 years

• History of coronary artery disease (documented by coronary angiogram, nuclear imaging, positive stress test)

• Stable cardiovascular medication for at least 1 month

• Written obtained informed consent

Exclusion Criteria:- myocardial infarction, unstable angina, stroke within 3 months prior to study entry

• coronary intervention/revascularisation procedure within 3 months prior to study entry

• Left ventricular ejection fraction <50%

• Other analgesics (Platelet inhibition therapy with Aspirin 100mg/d will be continued)

• Long acting nitrates

• Smoking

• Chronic heart failure (> NYHA II)

• Ventricular tachyarrhythmias

• Renal failure (serum creatinine >200umol)

• Liver disease (ALT or AST >100 IU), especially acute hepatitis

• Hyperbilirubinemia

• Alcohol abuse

• Oral Anticoagulation

• Concomitant therapy with Phenobarbital, Phenytoin, Carbamazepin, Isonicotinic Acid, Chloramphenicol Chlorzoxazone, Zidovudine, Salicylamide

• Insulin-dependent diabetes mellitus

• Drug abuse

• Anemia (Hb<10 g/dl)

• Known allergies on Paracetamol

• Pregnancy

• Malignancy (unless healed or remission > 5 years)

• Symptomatic hypotension, hypertension >160/100 mmHg

• Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn)

• Participation in another study within the last month